On November 11th, Bohui Innovation(300318) issued an announcement stating that its controlling subsidiary, Langfang Bohui, and Baihui Biotechnology jointly applied for the development of freeze-dried influenza B virus.The Haemophilus influenzae conjugate vaccine has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration, agreeing to conduct clinical trials. This vaccine is intended to prevent invasive infections caused by Haemophilus influenzae type b . The relevant application number is CXSL2500616, and the notification number is 2025LP02755.
　　The announcement states that drug development is characterized by high investment, high risk, and long cycles, and carries risks such as clinical trial results falling short of expectations and failure to obtain approval from relevant authorities. This receipt of the "Drug Clinical Trial Approval Notice" is considered a milestone in the development process and is not expected to have a significant impact on the company's recent performance.
　　In the first three quarters of 2025, Bohui Innovation achieved revenue of 629 million yuan and net profit attributable to the parent company of -33.62 million yuan.

https://finance.eastmoney.com/a/202511113561108525.html